Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The advances made in the 1980s and 1990s have yielded many advances in the diagnosis and treatment of depression and dysthymia. Skill of the clinician is important in sorting out the diagnosis, taking care to consider the various medical conditions that can cause depression or disguise themselves as depression. Depressive disorders are highly treatable conditions. Clinicians must overcome the stigma associated with these disorders to alleviate the pain and suffering of those afflicted. The advances in treatment have been enormous and continue to grow. The keys to these treatments lie in continuing to acquire the knowledge to unlock all of the causes of depression. An appendix follows listing medications commonly used in the treatment of depression or for other conditions in patients under treatment for depression.
 ...
PMID:Depression and dysthymia. 1134 77

Disclosure of the diagnosis of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) to a child is a controversial and emotionally laden issue. To understand the factors that affect the process of disclosure and its consequences, we studied 99 parent-child dyads recruited from patients being treated at the National Cancer Institute (NCI). Parents and HIV-infected children were interviewed and administered several standardized measures. Parental depression, family environment, social support satisfaction, socioeconomic status, child and parent gender, child's age, parental HIV serostatus, and disease severity were used to predict disclosure status. Results indicate that the majority of caregivers do disclose the diagnosis to the child, usually with no ill effects, and that age is the most significant predictor of whether or not a child has been told. The Centers for Disease Control and Prevention currently estimate that there are over 6611 children with AIDS (under age 13), and 2184 adolescents with AIDS (ages 13-19) in America. As an increasing number of children who are born infected with HIV live to older ages, the question of when and how to talk with them about their illness becomes more crucial. In addition to the growing number of children infected with HIV, there are many thousands of children profoundly affected by the impact of this disease on a close family member--a mother, father, sibling, or other relative in the kinship network. Yet, the initial reaction most adults have upon learning of their own, or of a family member's, HIV diagnosis is that the diagnosis must be kept a closely guarded secret. One reason frequently cited by parents and family members is their fear that the stigma of AIDS will have a negative impact on their children and their families. Disclosure of an HIV diagnosis to a child is a controversial and emotionally laden issue in the pediatric health-care community as well. However, no systematic research has studied the issues that surround disclosure of an HIV diagnosis to the patient and the factors that predict disclosure.
 ...
PMID:Factors associated with disclosure of diagnosis to children with HIV/AIDS. 1136 89

About forty million Americans will experience a major depressive illness sometime during their lives. However, many will not seek treatment because of the social stigma attached to the disorder--depression is a sign of weakness or failure. For those that do seek treatment, many alternatives are available. The first generation of antidepressants, dubbed tricyclics (TCAs), provide relief from depression, but produce severe side effects. Monoamine oxidase inhibitors (MAOIs) allow more norepinephrine, dopamine, and serotonin to be produced--neurotransmitters linked to moods and sleep. They also exhibit many side effects. The newest drugs, selective serotonin reuptake inhibitors (SSRIs), relieve depression similar to the TCAs and MAOIs, but have a lower rate of unpleasant side effects. Prozac, within the SSRI family, is the most popular and most studied drug for the treatment of depression. Discovered by pharmaceutical company Eli Lilly and approved by the Food and Drug Administration (FDA) in 1987, prozac has been shown to work against obsessive-compulsive disorder, suicidal thoughts, and aggressive behavior--all of which can be symptoms of depression.
 ...
PMID:Generation prozac. 1136 74

The study discussed in this article explored women's views of the positive and negative aspects of life with HIV. Even in the face of a stigmatizing physical illness and with elevated levels of depression and anxiety, the 55 women interviewed for the study were able to identify a large number of positive events; for many, HIV served as a motivating force for positive change. Common negative experiences included physical symptoms, a limited life span, alienation, and stigma. Results suggest that whereas women demonstrate a remarkable capacity to adapt, there are a number of specific areas where social services and community interventions can be targeted.
 ...
PMID:A female perspective on living with HIV disease. 1137 1

Potential solutions for barriers to improved organization of care of depressive illness were identified. These included (1) aligning efforts to improve depression care with broader strategies for improving care of other chronic conditions; (2) increasing the availability of depression case management services in primary care; (3) developing registries and reminder systems to ensure active follow-up of depressed patients; (4) achieving agreement on how depression outcomes should be measured to provide outcomes-based performance standards; (5) providing greater support from mental health specialists for management of depressed patients by primary care providers; (6) campaigns to reduce the stigma associated with treatment of depressive illness; (7) increased dissemination of interventions that activate and empower patients managing a depressive illness; (8) redefining the lack of time of primary care providers for high-quality depression care as issues in organization of care and provider training; and (9) development of incentives (organizational or financial) for high-quality depression care. Research needs were identified according to what has been learned to date. Identified research needs included: studies of approaches to organization of case management, research in new populations (e.g., new diagnostic groups, rural populations, the disadvantaged, the elderly, and those with chronic medical illnesses), research on stepped care and relapse prevention strategies, evaluation of the societal benefits of improved depression care, and multisite trials and meta-analytic approaches that can provide adequate statistical power to assess societal benefits of improved care.
 ...
PMID:Improving depression care: barriers, solutions, and research needs. 1140 51

Stigma attached to individuals with schizophrenia may be derived from its diagnostic label. Two forms of a questionnaire were distributed to 189 Japanese university students. Each questionnaire contains case vignettes of schizophrenia and major depression. In one form, the students were told at the close of each vignette the diagnostic label assigned to that case (the label group) whereas in another form, they were not done so (the control group). The students were also asked to rate negative image of the case in four items each. The label group was significantly higher than the control group in three of the four negative image items for the vignette of schizophrenia. They did not differ in any of the negative image items for the vignette of depression. This suggests that the label of schizophrenia (the Japanese translation Seishin-bunretsu-byou) has stigmatizing effect. We discussed these findings in the light of the implications of a relabeling, and argued for a change of name.
 ...
PMID:Labeling effect of Seishin-bunretsu-byou, the Japanese translation for schizophrenia: an argument for relabeling. 1143 10

Suicide and suicide attempts occur at a significantly greater rate in schizophrenia than in the general population. Common estimates are that 10% of people with schizophrenia will eventually have a completed suicide, and that attempts are made at two to five times that rate. Demographically associated with suicidality in schizophrenia are being young, being early in the course of the illness, being male, coming from a high socioeconomic family background, having high intelligence, having high expectations, not being married, lacking social supports, having awareness of symptoms, and being recently discharged from the hospital. Also associated are reduced self-esteem, stigma, recent loss or stress, hopelessness, isolation, treatment non-compliance and substance abuse. Clinically, the most common correlates of suicidality in schizophrenia are depressive symptoms and the depressive syndrome, although severe psychotic and panic-like symptoms may contribute as well. This review specifically explores the issue of depression in schizophrenia, in relation to suicide, by organizing the differential diagnosis of this state and highlighting their potentially treatable or correctable causes. This differential diagnosis includes both acute and chronic disappointment reactions, the prodrome of an acute psychotic episode, neuroleptic induced akinesia and akathisia, the possibility of direct neuroleptic-induced depression, negative symptoms of schizophrenia, and the possible co-occurrence of an independent depressive diathesis. The potential beneficial roles of 'atypical' antipsychotic agents, including both clozapine and more novel agents, and adjunctive treatment with other psychopharmacological medications are considered, and the important roles of psychosocial factors and interventions are recognized.
 ...
PMID:Suicide and schizophrenia. 1144 86

This article assesses the validity of the claim that welfare in itself has deleterious psychological consequences for single mothers. The analysis compares single mothers who are recipients of AFDC with single mothers who are not recipients in terms of their depressive symptoms (as measured by the CES-D) and hopelessness (as measured by Pearlin Mastery Scale). The analysis uses data from the National Longitudinal Survey of Youth and the National Survey of Families and Households. The authors find that higher levels of both depression and hopelessness among welfare recipients can be explained by their material hardship rather than the stigma attached to welfare. They show that AFDC recipients report similar levels of depression and hopelessness as jobless non-recipients as well as low-wage non-recipients. An additional finding is that long-term welfare recipients do not experience greater emotional problems than short-term welfare recipients. Finally, the paper shows that feelings of hopelessness mediate the relationship between material deprivation and psychological distress for both recipients and non-recipients.
 ...
PMID:Psychological distress, hopelessness and welfare. 1146 67

A pilot study of 29 patients for research on clinical depression employed the framework of cultural epidemiology to examine illness-related experience, meaning, behaviour with a Bengali version of the explanatory Model Interview Catalogue (EMIC). This report examined patterns of distress and stigma with reference to the most troubling patient-specified symptom. All subjects were psychiatric outpatients in the Institute of Psychiatry, Calcutta, and met Diagnostic and Statistical Manual (DSM)-IV criteria for a major depressive episode. Only 5 patients (17.2%) identified sadness as the most troubling problem, and 48.3% specified pains and other somatic symptoms instead. An internally consistent stigma scale with Cronbach's alpha of .67, comprised 13 items, was used to assess stigma. In addition to the scale score for each subject, the contribution of each item was reported and compared. A suggestive, though not significantly lower value of the stigma score for patients reporting somatic symptoms as most troubling, compared with sadness, was consistent with findings from prior studies showing a positive relationship between the magnitude of depression and stigma. These findings are discussed with reference to their impact on recognition and help seeking among patients, and recognition and management of depression by general practitioner. Culturally distinctive presentations and social contexts of depression and other mental illnesses should be addressed in professional training and public health communications.
 ...
PMID:Prominence of symptoms and level of stigma among depressed patients in Calcutta. 1148 Sep 52

This article examines the physical and mental health of African American mothers during a 2-year period following the birth of an infant seropositive for human immunodeficiency virus (HIV). Participants were 34 African American mothers enrolled when the infants were approximately 3 months of age and reinterviewed when the infants were 6, 12, 18, and 24 months. Three self-report questionnaires were used to assess physical health (perception of health, activity limitation, and physical symptoms) and mental health (depressive symptoms and stigma). Health symptoms most often reported were infections, problems thinking and remembering, low energy, and gynecologic problems. Moderate levels of perceived stigma were reported. Depressive symptoms were high; a large number of women at each data point had depressive symptom scores above the cutoff, indicating risk for depression. There were significant correlations between depressive symptoms and health, suggesting a link between mental and physical health. These findings have significance for the health of the mother and the parenting of her infant. Attention should be paid to the mental and physical health of mothers with HIV, especially during the first 2 years after the birth of a child.
 ...
PMID:Physical and mental health in African American mothers with HIV. 1148 19


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>